Sotera Health arrives at mid-week with an unusual combination: short interest up nearly 47% over the past month while Goldman Sachs has just stepped in with a fresh Buy rating and Barclays lifted its target on Tuesday.
The analyst picture is the clearest bullish signal in this setup. Goldman initiated coverage on June 5 with a Buy and a $20 target — the first bellwether firm to formally step into the name. Barclays followed on June 24, raising its target from $18 to $19 while keeping an Overweight rating. Piper Sandler also holds Overweight, though it trimmed its target to $22 from $24 following the Q1 report. The consensus target of $20.22 implies roughly 28% upside from the current $15.84. JP Morgan sits on the sidelines at Neutral with a $16 target — the most cautious voice — but it is a minority position. The Street is broadly constructive, with recent initiations from BMO Capital, William Blair, and RBC all carrying Outperform equivalents. Analyst momentum is running in one direction: up.
Short positioning tells a more complicated story. Bears rebuilt aggressively through late May and early June, lifting SI as a percentage of free float from roughly 4.5% to 6.8% — a 46% jump in a month. That is a material shift, not noise. The recent history shows the spike was concentrated around June 8, when shares short briefly touched 20.7 million before easing back toward 19.4 million by June 23. The one-week change is now just +0.14%, suggesting the initial rebuild has plateaued. Borrow conditions are not tight. Availability runs near 969% — meaning roughly nine shares are available to borrow for every one already lent out, comfortably in normal territory. Cost to borrow has more than doubled week-on-week to 0.52% but remains very low in absolute terms. Nothing in the lending market suggests shorts are under pressure.
Options positioning has turned more call-heavy than usual. The put/call ratio of 0.07 is more than four standard deviations above its 20-day mean — a reading that sounds alarming until you see the actual numbers: PCR of 0.0713 versus a mean of 0.0588. The 52-week range stretches from 0.0007 to 51.15, so the current reading is extreme only relative to a very compressed recent baseline, not relative to the broader range. The options market has been unusually call-dominated for weeks. Call buyers have been active since mid-May when puts were far more prevalent.
The ownership picture adds texture to the bullish analyst narrative. Active managers hold the stock in size: Darsana Capital holds 9.1%, Sessa Capital 8.1%, and Sculptor 7.6%. Sachem Head Capital added 3.9 million shares in a recent filing. BlackRock added 2.8 million shares through May. The active manager concentration suggests holders have strong conviction at current prices. The sharp counter-note comes from the sponsor exit: Warburg Pincus and GTCR together sold roughly 57 million shares at around $15.17-$15.27 on May 13, a combined disposition worth close to $483 million. That overhang is now largely cleared, which may explain why the short interest spike stabilised quickly and why active managers kept adding through the same period.
Valuation is undemanding. EV/EBITDA runs at 9.9x, the P/E at 15.6x. Both multiples have drifted slightly lower over the past week but are broadly flat over 30 days. The ORTEX short score of 54.3 sits in the middle of its recent range — neither extreme — and the factor composite scores earnings momentum (56-58th percentile) as constructive while EPS surprise (20th percentile) and forward-year EPS growth (24th percentile) rank low. The dividend score of 77 suggests income credentials the headline PE does not immediately reveal.
Q1 results printed a clean +2.7% one-day gain and held most of that into the five-day window. The next print is due August 6. The question going into that date is whether the short rebuild over the past month reflects genuine fundamental concern or was principally a technical response to the sponsor overhang — and whether the Goldman and Barclays upgrades are early reads on Q2 that would shift that calculus.
See the live data behind this article on ORTEX.
Open SHC on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
